{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6O7e0LDA","lastupdate":"2022-12-08T00:00:00.000Z","update_date":"2022-12-08T00:00:00.000Z","lastModified":"Oct 24, 2025","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"diagnostear","minimal_profile":null,"status":"Public","fullstatus":"Public on CSE on Dec, 2024;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$g5SBUPavRy9zSkwQvMCEC7skr2dpVAoJodetPcamACS84vWj1LXID9","name":"DiagnosTear","oneliner":"Screening and Monitoring Kit for Dry Eye Syndrome","registrar":"514733765","website":"https://bio-light.co.il/diagnos-tear/","careerspage":"","founded_month":9,"founded_year":2013,"formernames":["D.I.S. Diagnostics"],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UC7ppZLxB5fTTgulP3Xh1wHA","facebook":"","linkedin":"https://www.linkedin.com/company/27090167","instagram":""},"social":["https://www.youtube.com/channel/UC7ppZLxB5fTTgulP3Xh1wHA","https://www.linkedin.com/company/27090167"],"flattenedsociallinks":"https://www.youtube.com/channel/UC7ppZLxB5fTTgulP3Xh1wHA|https://www.linkedin.com/company/27090167","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":8,"patent":1,"raised":4550000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Diagnos.Tear","TeaRx","BioLight","Diagnose-tear","Diagnose Tear"],"about":"DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome. The company is developing an assay designed to facilitate the diagnosis, treatment, and monitoring of dry eye syndrome by examining certain parameters in tear fluid.\r\n\r\nDiagnosTears TeaRx assay is based on various reagents that create color reactions when coming into contact with tear film, allowing for a semi-quantitative assessment of the parameters that define the syndrome. Information on the parameters assists in the diagnosis of the syndrome and enables a better, more informed selection of treatment and monitoring options.\r\n\r\nTeaRx enables the monitoring and screening of the condition by examining up to five different varieties of tear fluid. The test is carried out through the use of a simple device that is placed under the lower eyelid to absorb the tear fluid.\r\n\r\nDiagnosTear is an XLVision Sciences company and a fully owned subsidiary of BioLight.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972732753400","country":null,"address":{"israeli":[{"id":"d85c0b73-c525-4ff8-a763-54c322b17b4a","city":"Tel Aviv-Yafo","type":null,"address":"Kiryat Atidim, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"liQqVAoxfgrEimEVygBbMSAnSWYYvsjhYQXtHloE1IICLIsqpS99Ma","date":"Oct 24, 2025","link":"https://finance.yahoo.com/news/diagnostear-technologies-inc-announces-upsizing-123700707.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment","round":null,"company":"DiagnosTear Technologies Inc.","layoffs":null,"summary":"DiagnosTear Technologies Inc., an ophthalmic company, announced an increase in its non-brokered private placement offering to up to 2,000,000 units, aiming to raise $1,000,000. Each unit consists of one common share and one warrant, with the warrant exercisable at $1.00 for 18 months. The funds will support working capital and general corporate purposes. The offering is expected to close by November 5, 2025, subject to compliance with Canadian Securities Exchange requirements. DiagnosTear is known for its TeaRx™ technology, a diagnostic platform for ophthalmic pathologies, including a CE-IVD and Israeli MoH-approved test for Dry Eye Syndrome. The product is not yet FDA-cleared, and the company is developing additional tests for other eye conditions.","partners":null,"customers":null,"eventType":"PIPE","investors":null,"confidence":10,"key_topics":["Investment","Ophthalmic","Diagnostics","Technology","Offering"],"date_of_event":"October 24, 2025","product_stage":"released","investment_date":"October 24, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1,000,000","structured_issues":["PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LQha7XzYmgIhPAaNfr9jRicqGCymMlo7GySpf54E3ECBGWI2wrEw0r","news_summary":"DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Dqtccux4VTBdbAGUOec6IxB86CgqdIEKId12TcZczui45yPXPUYzCu","date":"Oct 22, 2025","link":"https://finance.yahoo.com/news/diagnostear-announces-frankfurt-stock-exchange-123500942.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"expansion","round":null,"company":"DiagnosTear Technologies Inc.","layoffs":null,"summary":"DiagnosTear Technologies Inc. has announced the listing of its common shares on the Frankfurt Stock Exchange, marking a significant milestone in its expansion into European capital markets. This move is expected to enhance the companys visibility and trading liquidity, particularly in a region known for its focus on healthcare innovation. Additionally, DiagnosTear has engaged bullVestor Medien GmbH for marketing services to support its presence in the German market. The agreement with bullVestor, valued at €300,000, aims to increase awareness and engagement with European investors. The listing and marketing efforts are part of DiagnosTears strategy to strengthen its international presence and foster relationships with institutional and retail investors across Europe.","partners":["bullVestor Medien GmbH"],"customers":null,"eventType":"Public Trading","investors":null,"confidence":10,"key_topics":["Frankfurt Listing","Marketing Services","European Expansion","Investor Relations","Healthcare Innovation"],"date_of_event":"October 22, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading","Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Public Trading  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hHnGkrkbarjMaWCXFMUCTwrg8sFHO1xhazMtn2RA75x3kFgazzIClF","news_summary":"DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"j9DujLcQcFhFWqvq1mBLIYQ1KZhS3TuWEVZvOmTIqx72NJq3sXdp4x","date":"Jun 2, 2025","link":"https://www.tipranks.com/news/company-announcements/diagnostear-technologies-announces-700000-private-placement-to-enhance-financial-position","source":"www.tipranks.com","visible":1,"analysis":{"tags":"Investment","round":null,"company":"DiagnosTear Technologies, Inc.","layoffs":null,"summary":"DiagnosTear Technologies, Inc., a company specializing in ophthalmic diagnostic solutions, announced a non-brokered private placement to raise $700,000 through the sale of 1,400,000 units at $0.50 per unit. Each unit includes one common share and one warrant, exercisable at $1.00 within 18 months. The funds will be used for working capital and general corporate purposes, supporting the companys development of diagnostic solutions in the ophthalmic industry. DiagnosTears flagship technology, TeaRx™, is a diagnostic platform for rapid, Point-of-Care Testing of ophthalmic pathologies, and the company is expanding its pipeline to include tests for various eye conditions.","partners":null,"customers":null,"eventType":"PIPE","investors":null,"confidence":9,"key_topics":["Investment","Ophthalmic","Diagnostics","Private Placement","Technology"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$700,000","structured_issues":["Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3pCWTSjeQCIkP7XKVWtD1ARZY7iO5zxEeg0twFzMuEQJQPWONaslXf","news_summary":"DiagnosTear Technologies Announces $700,000 Private Placement to Enhance Financial Position - TipRanks.com","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4mPWhgkNUr3kB5ytlQFpq7IgJBO5Heuj2EtJaf8ORl52kQevJMkwGI","date":"Jan 16, 2025","link":"https://finance.yahoo.com/news/canadian-securities-exchange-reports-2024-192800622.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"market statistics","round":null,"company":"Canadian Securities Exchange","layoffs":null,"summary":"The Canadian Securities Exchange (CSE) reported strong growth in financing activity for 2024, with a significant increase in the number of financings and total capital raised compared to 2023. The CSE introduced 45 new corporate listings, including 11 IPOs, and completed 1,140 financings raising $2.1 billion. Trading activity also increased, with 13.1 billion shares traded and a trading value of $4.0 billion. The CSEs membership in the World Federation of Exchanges and participation in the upcoming Vancouver Resource Investment Conference highlight its efforts to strengthen its position. The CSEs growth is attributed to interest rate cuts and high metal prices, which have fueled investor interest.","partners":null,"customers":null,"eventType":"IPO","investors":null,"confidence":9,"key_topics":["financing","listings","trading","investment","conferences"],"date_of_event":"January 16, 2025","product_stage":"released","investment_date":"2024","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$2.1 billion","structured_issues":["Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"64md8i5yleqJPqyHTUJzSg2YKIodmp08blyd4rd5jS7uGmE722gTBR","news_summary":"Canadian Securities Exchange Reports 2024 Performance Figures","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sPYIuAOaA74hombJOXyc6Jz3sseHR0WXTnsefuaGBZGLpTFzDEwNpX","date":"Dec 9, 2024","link":"https://finance.yahoo.com/news/canadian-securities-exchange-welcomes-listing-194400448.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"public listing","round":null,"company":"DiagnosTear Technologies Inc.","layoffs":null,"summary":"DiagnosTear Technologies Inc., an Israel-based ophthalmic company, has been listed on the Canadian Securities Exchange (CSE) under the symbol DTR. The company specializes in developing and commercializing diagnostic solutions for eye diseases, focusing on its TeaRx™ technology for rapid, point-of-care testing through tear fluid. DiagnosTear aims to become a global leader in ocular disease diagnostics, particularly for conditions like dry eye and red eye. The listing on the CSE marks a significant step in the companys growth, providing access to public capital markets and enhancing its global liquidity.","partners":null,"customers":null,"eventType":"IPO","investors":null,"confidence":9,"key_topics":["CSE listing","diagnostic solutions","eye diseases","TeaRx technology","point-of-care"],"date_of_event":"December 9, 2024","product_stage":"developing","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pNchtcsfwifhHI1c4MALFTWJA4UHxtIs9EYdW0v08MGgqkb0aYD5iM","news_summary":"Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"vLfamfdngGUnqnMJf3AvDScFB0DIlyniEkMlITAVa0Ovo9wZBrZHMm","date":"Dec 8, 2024","link":"https://finance.yahoo.com/news/canadian-securities-exchange-welcomes-listing-194400448.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"public listing","company":"DiagnosTear Technologies Inc.","layoffs":null,"summary":"DiagnosTear Technologies Inc., an Israel-based ophthalmic company, has successfully listed its common shares on the Canadian Securities Exchange (CSE) under the symbol DTR. The company specializes in developing diagnostic solutions for eye diseases, utilizing its TeaRx™ technology for rapid, point-of-care testing through tear fluid. The listing marks a significant step for DiagnosTear as it aims to become a global leader in ocular disease diagnostics. The CSE is recognized for supporting emerging companies with innovative technologies, and DiagnosTears listing is expected to enhance its visibility and access to public capital markets. The companys focus on non-invasive, easy-to-use diagnostic tools aligns with its goal of providing personalized treatment options for conditions like dry eye and red eye.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["CSE listing","diagnostic solutions","eye diseases","TeaRx technology","point-of-care"],"date_of_event":"December 9, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EllHZGJE0ibGscx925SIZGXrkus65lxZztonwFs6H48mNDB1vjgpVO","news_summary":"Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QHzkM2fMsKcDqd8G1WKdLVlbt5XQeVKgv5ioEvmYv8R3ZMn4F75dby","date":"Jun 11, 2023","link":"https://www.biospace.com/diagnostear-a-subsidiary-of-biolight-life-sciences-ltd-signed-a-binding-letter-of-intent-for-merger-capital-raise-and-listing-on-the-canadian-securities-exchange","source":"www.biospace.com","visible":1,"analysis":{"tags":"merger","company":"BioLight","layoffs":null,"summary":"BioLight, a company specializing in investments in biomed companies focusing on eye diseases, announced that its subsidiary, Diagnostear, has entered into a binding LOI for a merger with a Canadian corporation. This merger will allow Diagnostear to list its shares on the Canadian Securities Exchange with an estimated value of US$ 33.5 million. BioLight will hold approximately 50% of the shares in the merged company. As part of the merger, Diagnostear will raise US$ 1 million, and the Canadian corporation will raise US$ 2.5 million. The funds will support Diagnostears business plan, including the development of eye tests based on tear fluid analysis. The merger aims to enhance Diagnostears market presence and product development.","partners":null,"customers":null,"investors":"Canadian corporation","confidence":9,"key_topics":["Merger","Investment","Eye diseases","Tear analysis","Product development"],"date_of_event":"June 5 2023","valuation_amount":"33.5 million","impact_on_company":"growth-positive","investment_amount":"1 million","structured_issues":["Acquired-by","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Acquired-by  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9snF53wmE4MjuJqkPoAGWOxbttaeRwPjUywojh3iwkLWSS8HIQvSuG","news_summary":"Diagnostear, a subsidiary of BioLight Life Sciences Ltd, signed a binding Letter of Intent for merger, capital raise and listing on the Canadian Securities Exchange","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"94bba737-946f-4d1e-a085-454fbeff3b95","date":"Oct 19, 2021","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_1996401_0_Txtetaxjxdshwhus8sp&ArticleId=106595","source":"www.sponser.co.il","visible":1,"analysis":{"tags":"clinical trial","company":"ביולייט","layoffs":null,"summary":"Israeli company BioLight announced that its subsidiary DiagnosTear has enrolled the first participant in a clinical trial in India. The trial is part of a commercial collaboration agreement with an international pharmaceutical company and the LV Prasad Eye Institute. DiagnosTear, which is 82% owned by BioLight, develops the TeaRx technology for diagnosing eye diseases by analyzing tear fluid composition and personalizing and monitoring treatment for dry eye syndrome. The clinical trial aims to evaluate the products capabilities in diagnosing and treating patients with dry eye syndrome and will involve approximately 600 participants over a period of up to 6 months.","partners":"LV Prasad Eye Institute","customers":null,"investors":null,"confidence":8,"key_topics":["clinical trial","eye diseases","diagnostics","LV Prasad Eye Institute","dry eye syndrome"],"date_of_event":"2020-06","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Gin61E8ELGw60h1CSnFpVik9Suqr4nS2dhAChEEdc7I0OdCz3VqiBw","news_summary":"ביולייט מגייסת נבדק ראשון בהודו לניסוי קליני לאבחון מחלות עיניים","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"23e7ddcc-ee33-414d-aa44-f1f61451234a","date":"Feb 23, 2017","link":"https://www.prnewswire.com/news-releases/biolights-tearx-multi-parameter-diagnostic-assays-to-be-used-in-dry-eye-syndrome-drug-trial-614592693.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"BioLight Life Sciences Ltd.","layoffs":null,"summary":"BioLights subsidiary, DiagnosTear, has signed a services agreement with a pharmaceuticals company for the use of its TeaRx diagnostic assays in a clinical trial for dry eye syndrome. This marks the first time TeaRx will be used in a drug trial. The collaboration may lead to a joint-development project for a potential companion diagnostics solution. BioLight aims to address the unmet medical need for personalized treatment of DES. Dry eye syndrome affects millions of people worldwide. BioLights key investors include Mr. Israel Makov, Mr. Dilip Shanghvi, Mr. Dan Oren, and Rock-One.","partners":"pharmaceuticals company","customers":null,"investors":["Mr. Israel Makov","Mr. Dilip Shanghvi","Mr. Dan Oren","Rock-One"],"confidence":9,"key_topics":["DiagnosTear","TeaRx","dry eye syndrome","personalized treatment","DES therapeutics"],"date_of_event":"February 23, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vhU0Uy1jvvAp9ZhzhVc9uNvtDCtZvRDVdqWN71MkbC7p14k1QVyQTG","news_summary":"BioLight's TeaRx Multi-Parameter Diagnostic Assays to be Used in Dry Eye Syndrome Drug Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5bfcb602-6bb0-4d16-b85d-f5d81086ada2","date":"Oct 4, 2014","link":"http://www.prnewswire.com/news-releases/biolight-announces-start-of-clinical-study-with-diagnostear-dry-eye-syndrome-diagnostic-assay-244710141.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Clinical Study, Dry Eye Syndrome","company":"BioLight Life Sciences Investments Ltd.","layoffs":"Not mentioned","summary":"BioLight Life Sciences Investments Ltd. has announced that DiagnosTear Ltd. has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay. The study aims to validate the effectiveness of the test methods developed by DiagnosTear. The diagnostic assay has stimulated strong interest among leading ophthalmic companies and key opinion leaders worldwide. DiagnosTear is preparing to add another center in Israel to the clinical study soon and expects to report its results in the fourth quarter of 2014.","partners":"Sheba Medical Center","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Study","Dry Eye Syndrome","Diagnostic Assay","Market Analysis","XLVision Sciences"],"date_of_event":"Feb. 10, 2014","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Lpipudzr1qdnxNRBQCyUjssb1Txtz4HsgiBHPKxwtgwGrA7ddu9f2l","news_summary":"BioLight Announces Start of Clinical Study with DiagnosTear Dry Eye Syndrome Diagnostic Assay","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":10,"techcommunityinvolvement":null,"mediagallery":[{"id":"07548632-70cf-425e-b1ad-76240ee0e41b","timestamp":"2020-04-30 12:13:57.000000","resources_type":2,"resources_title":"DiagnosTear - TeaRx","resources_file_name":"qt2-S8FJiPM","alt":"DiagnosTear - TeaRx logo","imageurl":"https://img.youtube.com/vi/qt2-S8FJiPM/0.jpg","url":"http://youtu.be/qt2-S8FJiPM"}],"tags":["eye-diseases","ophthalmology","diagnostics","medical-devices","non-invasive","monitoring","healthcare-providers","medical-technologies","personalization","clinics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["TeaRx"],"geomarkets":["Global","India"],"targetmarkets":[],"marketcapital":20918882,"marketcapitaldate":"2025-11-01T14:05:35.000Z","funding":{"investors":2,"lastfunding":"$700K","totalrounds":4,"fundingstage":"Public","totalfunding":"$4.55M","publicinvestors":2,"lastpublicfunding":700000,"totalpublicrounds":4,"totalpublicfunding":4550000},"team":[{"name":"Eran Eilat","email":"eilat@diagnostear.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGhppIKDA","bounced":true,"claimed":0,"founder":1,"urlname":"eran-eilat-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA0YeZxAkM","position":"Founder & CEO","last_name":"Eilat","claimtoken":"NJkIJMWzNjQjXUkCR2syvsxUnLeU8fiCUv1M8Xx65v3sGDHhScGxdf","first_name":"Eran","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eran-eilat-3462115/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-08 17:53:01.000000","initials":"EE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Amos  Sommer","email":"amos@diagnostear.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGywJUKDA","bounced":false,"claimed":0,"founder":0,"urlname":"amos-sommer","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgnpLUoAoM","position":"COO","last_name":"Sommer","claimtoken":"XIWd9oKkjv4VmJcSOilJ4OHTEtH0Mu6JdR7Dprok2QC8nIruW8RFcV","first_name":"Amos ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/amossommerivd/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-08 17:53:03.000000","initials":"AS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2020-04-30T00:00:00.000Z","crunchbaseid":"diagnostear","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Arielle Smolin","creator_email":"ari.smolin@gmail.com","createdate":"2014-07-08T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"RfmPslyDtAeAGumoL9FHDRWCJ4Vxq01y40wMOGcUxtOahJ5ZHwbtgI","date":"Jun 2025","amount":"$700K","source":"https://www.tipranks.com/news/company-announcements/diagnostear-technologies-announces-700000-private-placement-to-enhance-financial-position","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"ZFoDNJFexS6YylFUCSVkXxk1LYVt4PS6lY4LczdRdgCkZHJNoFWwFB","date":"Dec 2024","amount":"Undisclosed","source":"https://finance.yahoo.com/news/canadian-securities-exchange-welcomes-listing-194400448.html","ticker":"DTR","eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"CSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDgvYSZCQw","stockexchange_logokey":"$sMnyNNSNfU5nNScoSE2pPxbUwmDZcF8ZZBZKxcJSZSdnbqGSX2RieV","acquiredcompany_reverse":"Canadian Corporation","acquiredcompany_reverse_id":"QOKkjjTPggS8Zt91k0D303ocBVH9YLQLFqugrs4jIiSQ0CxApcgwLZ","acquiredcompany_reverse_type":"Multinational","acquiredcompany_reverse_hidden":true,"acquiredcompany_reverse_fullurl":"/mnc_page/canadian-corporation","acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":"/mnc_page/canadian-corporation","acquiredcompany_reverse_homepage":"https://www.canada.com","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$sMnyNNSNfU5nNScoSE2pPxbUwmDZcF8ZZBZKxcJSZSdnbqGSX2RieV","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODVxYKYCww","date":"Oct 2020","amount":"$3.85M","source":"https://www.funder.co.il/article/112150, https://www.facebook.com/ElcamMedical/","eventtype":"FundingRoundEvent","investment":[{"name":"Elcam Medical","type":"Startup","amount":0,"hidden":true,"country":"Israel","fullurl":"/company_page/elcam-medical","logokey":"$FE9jcv2ozzIq9zZyAKVvURGaHvj1mErEwjVZSC4YUMmmMTG3k8CjRE","tagline":"Producer of disposable medical devices","urlname":"/company_page/elcam-medical","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7ezpsJDA","fundingtype":"Startup","leadpartner":null,"investmentid":"3794f9e9-4bf4-4747-9aec-22c5f563dbf5","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$FE9jcv2ozzIq9zZyAKVvURGaHvj1mErEwjVZSC4YUMmmMTG3k8CjRE","leadcaption":"","followupcaption":""},{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ce002229-c5df-4b52-ba0b-37b3a6398970","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3850000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCs4OjvCAw","date":"Oct 2015","amount":"Undisclosed","source":"","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"dd98953b-0f5e-4a0c-be6a-b446d5e9734c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE3_ugCww","date":"May 2014","amount":"Undisclosed","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d86fd754-b4c4-46b4-a140-d2ddf1e97337","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"9/2013","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"DiagnosTear","logourl":"https://storage.googleapis.com/clean-finder-353810/$g5SBUPavRy9zSkwQvMCEC7skr2dpVAoJodetPcamACS84vWj1LXID9","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$g5SBUPavRy9zSkwQvMCEC7skr2dpVAoJodetPcamACS84vWj1LXID9","seoabout":"DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome. The company is developing an assay designed to facilitate the di...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Diagnostics Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Diagnostics Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Diagnostics Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Diagnostics Devices","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Diagnostics Devices"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Diagnostics Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Diagnostics Devices"],"coreTechnology":[],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"ZFoDNJFexS6YylFUCSVkXxk1LYVt4PS6lY4LczdRdgCkZHJNoFWwFB","date":"Dec 2024","amount":"Undisclosed","source":"https://finance.yahoo.com/news/canadian-securities-exchange-welcomes-listing-194400448.html","ticker":"DTR","eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"CSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDgvYSZCQw","stockexchange_logokey":"$sMnyNNSNfU5nNScoSE2pPxbUwmDZcF8ZZBZKxcJSZSdnbqGSX2RieV","acquiredcompany_reverse":"Canadian Corporation","acquiredcompany_reverse_id":"QOKkjjTPggS8Zt91k0D303ocBVH9YLQLFqugrs4jIiSQ0CxApcgwLZ","acquiredcompany_reverse_type":"Multinational","acquiredcompany_reverse_hidden":true,"acquiredcompany_reverse_fullurl":"/mnc_page/canadian-corporation","acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":"/mnc_page/canadian-corporation","acquiredcompany_reverse_homepage":"https://www.canada.com","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$sMnyNNSNfU5nNScoSE2pPxbUwmDZcF8ZZBZKxcJSZSdnbqGSX2RieV","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[{"id":"RfmPslyDtAeAGumoL9FHDRWCJ4Vxq01y40wMOGcUxtOahJ5ZHwbtgI","date":"Jun 2025","amount":"$700K","source":"https://www.tipranks.com/news/company-announcements/diagnostear-technologies-announces-700000-private-placement-to-enhance-financial-position","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODVxYKYCww","date":"Oct 2020","amount":"$3.85M","source":"https://www.funder.co.il/article/112150, https://www.facebook.com/ElcamMedical/","eventtype":"FundingRoundEvent","investment":[{"name":"Elcam Medical","type":"Startup","amount":0,"hidden":true,"country":"Israel","fullurl":"/company_page/elcam-medical","logokey":"$FE9jcv2ozzIq9zZyAKVvURGaHvj1mErEwjVZSC4YUMmmMTG3k8CjRE","tagline":"Producer of disposable medical devices","urlname":"/company_page/elcam-medical","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7ezpsJDA","fundingtype":"Startup","leadpartner":null,"investmentid":"3794f9e9-4bf4-4747-9aec-22c5f563dbf5","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$FE9jcv2ozzIq9zZyAKVvURGaHvj1mErEwjVZSC4YUMmmMTG3k8CjRE","leadcaption":"","followupcaption":""},{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ce002229-c5df-4b52-ba0b-37b3a6398970","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3850000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCs4OjvCAw","date":"Oct 2015","amount":"Undisclosed","source":"","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"dd98953b-0f5e-4a0c-be6a-b446d5e9734c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE3_ugCww","date":"May 2014","amount":"Undisclosed","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d86fd754-b4c4-46b4-a140-d2ddf1e97337","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}